Loading...
Header Logo
Keywords
Last Name
Institution

Andrew L Frelinger PhD

TitleAdjunct Associate Professor
InstitutionUniversity of Massachusetts Medical School
DepartmentPediatrics
AddressChildrens Hospital Boston
300 Longwood Avenue
Boston MA 02115
Phone617-919-2537
vCardDownload vCard
    Other Positions
    InstitutionUMMS - School of Medicine
    DepartmentPediatrics
    DivisionHematology Oncology


    Collapse Biography 
    Collapse education and training
    San Diego State University, San Diego, CA, United StatesBSBiology
    Case Western Reserve University, Cleveland, OH, United StatesPHDBiology

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    List All   |   Timeline
    1. Garner AL, Frelinger AL, Gerrits AJ, Gremmel T, Forde EE, Carmichael SL, Michelson AD, Neculaes VB. Using extracellular calcium concentration and electric pulse conditions to tune platelet-rich plasma growth factor release and clotting. Med Hypotheses. 2019 Apr; 125:100-105. PMID: 30902134.
      View in: PubMed
    2. Charnigo RJ, Beidler D, Rybin D, Pittman DD, Tan B, Howard J, Michelson AD, Frelinger AL, Clarke N. PF-04447943, a Phosphodiesterase 9A Inhibitor, in Stable Sickle Cell Disease Patients: A Phase Ib Randomized, Placebo-Controlled Study. Clin Transl Sci. 2018 Dec 31. PMID: 30597771.
      View in: PubMed
    3. Smolensky Koganov E, Michelson AD, Yanachkov IB, Yanachkova MI, Wright GE, Przyklenk K, Frelinger AL. Publisher Correction: GLS-409, an Antagonist of Both P2Y1 and P2Y12, Potently Inhibits Canine Coronary Artery Thrombosis and Reversibly Inhibits Human Platelet Activation. Sci Rep. 2018 Nov 29; 8(1):17580. PMID: 30498241.
      View in: PubMed
    4. Koganov ES, Michelson AD, Yanachkov IB, Yanachkova MI, Wright GE, Przyklenk K, Frelinger AL. GLS-409, an Antagonist of Both P2Y1 and P2Y12, Potently Inhibits Canine Coronary Artery Thrombosis and Reversibly Inhibits Human Platelet Activation. Sci Rep. 2018 Sep 28; 8(1):14529. PMID: 30266987.
      View in: PubMed
    5. Frelinger AL, Gerrits AJ, Neculaes VB, Gremmel T, Torres AS, Caiafa A, Carmichael SL, Michelson AD. Tunable activation of therapeutic platelet-rich plasma by pulse electric field: Differential effects on clot formation, growth factor release, and platelet morphology. PLoS One. 2018; 13(9):e0203557. PMID: 30256831.
      View in: PubMed
    6. Blair TA, Michelson AD, Frelinger AL. Mass Cytometry Reveals Distinct Platelet Subtypes in Healthy Subjects and Novel Alterations in Surface Glycoproteins in Glanzmann Thrombasthenia. Sci Rep. 2018 Jul 09; 8(1):10300. PMID: 29985398.
      View in: PubMed
    7. Gremmel T, Michelson AD, Frelinger AL, Bhatt DL. Novel aspects of antiplatelet therapy in cardiovascular disease. Res Pract Thromb Haemost. 2018 Jul; 2(3):439-449. PMID: 30046748.
      View in: PubMed
    8. Frelinger AL. Using flow cytometry to monitor glycoprotein IIb-IIIa activation. Platelets. 2018 May 25; 1-7. PMID: 29799301.
      View in: PubMed
    9. Nwankwo JO, Gremmel T, Gerrits AJ, Mithila FJ, Warburton RR, Hill NS, Lu Y, Richey LJ, Jakubowski JA, Frelinger AL, Chishti AH. Calpain-1 regulates platelet function in a humanized mouse model of sickle cell disease. Thromb Res. 2017 Dec; 160:58-65. PMID: 29101791.
      View in: PubMed
    10. Haynes RL, Frelinger AL, Giles EK, Goldstein RD, Tran H, Kozakewich HP, Haas EA, Gerrits AJ, Mena OJ, Trachtenberg FL, Paterson DS, Berry GT, Adeli K, Kinney HC, Michelson AD. High serum serotonin in sudden infant death syndrome. Proc Natl Acad Sci U S A. 2017 07 18; 114(29):7695-7700. PMID: 28674018.
      View in: PubMed
    11. Bhatt DL, Grosser T, Dong JF, Logan D, Jeske W, Angiolillo DJ, Frelinger AL, Liang J, Cryer B, Marathi U. Reply: Collapse of the Aspirin Empire: Is it Diabetic Gastroparesis or Cardioprotective Paresis? J Am Coll Cardiol. 2017 Jun 13; 69(23):2879. PMID: 28595709.
      View in: PubMed
    12. Bhatt DL, Grosser T, Dong JF, Logan D, Jeske W, Angiolillo DJ, Frelinger AL, Lei L, Liang J, Moore JE, Cryer B, Marathi U. Enteric Coating and Aspirin Nonresponsiveness in Patients With Type 2 Diabetes Mellitus. J Am Coll Cardiol. 2017 Feb 14; 69(6):603-612. PMID: 28089180.
      View in: PubMed
    13. Gerrits AJ, Frelinger AL, Michelson AD. Whole Blood Analysis of Leukocyte-Platelet Aggregates. Curr Protoc Cytom. 2016 Oct 10; 78:6.15.1-6.15.10. PMID: 27723089.
      View in: PubMed
    14. Frelinger AL, Gerrits AJ, Garner AL, Torres AS, Caiafa A, Morton CA, Berny-Lang MA, Carmichael SL, Neculaes VB, Michelson AD. Modification of Pulsed Electric Field Conditions Results in Distinct Activation Profiles of Platelet-Rich Plasma. PLoS One. 2016; 11(8):e0160933. PMID: 27556645.
      View in: PubMed
    15. Jain A, van der Meer AD, Papa AL, Barrile R, Lai A, Schlechter BL, Otieno MA, Louden CS, Hamilton GA, Michelson AD, Frelinger AL, Ingber DE. Assessment of whole blood thrombosis in a microfluidic device lined by fixed human endothelium. Biomed Microdevices. 2016 Aug; 18(4):73. PMID: 27464497.
      View in: PubMed
    16. Carreras ET, Hochholzer W, Frelinger AL, Nordio F, O'Donoghue ML, Wiviott SD, Angiolillo DJ, Michelson AD, Sabatine MS, Mega JL. Diabetes mellitus, CYP2C19 genotype, and response to escalating doses of clopidogrel. Insights from the ELEVATE-TIMI 56 Trial. Thromb Haemost. 2016 Jul 4; 116(1):69-77. PMID: 27009617.
      View in: PubMed
    17. Gremmel T, Frelinger AL, Michelson AD. Platelet Physiology. Semin Thromb Hemost. 2016 Apr; 42(3):191-204. PMID: 26926581.
      View in: PubMed
    18. Gremmel T, Yanachkov IB, Yanachkova MI, Wright GE, Wider J, Undyala VV, Michelson AD, Frelinger AL, Przyklenk K. Synergistic Inhibition of Both P2Y1 and P2Y12 Adenosine Diphosphate Receptors As Novel Approach to Rapidly Attenuate Platelet-Mediated Thrombosis. Arterioscler Thromb Vasc Biol. 2016 Mar; 36(3):501-9. PMID: 26743169.
      View in: PubMed
    19. Gremmel T, Michelson AD, Frelinger AL. In Vivo and protease-activated receptor-1-mediated platelet activation in patients presenting for cardiac catheterization. Platelets. 2016 Jun; 27(4):308-16. PMID: 26556638.
      View in: PubMed
    20. Yanachkov IB, Chang H, Yanachkova MI, Dix EJ, Berny-Lang MA, Gremmel T, Michelson AD, Wright GE, Frelinger AL. New highly active antiplatelet agents with dual specificity for platelet P2Y1 and P2Y12 adenosine diphosphate receptors. Eur J Med Chem. 2016 Jan 01; 107:204-18. PMID: 26588064.
      View in: PubMed
    21. Brun C, Daali Y, Combescure C, Zufferey A, Michelson AD, Fontana P, Reny JL, Frelinger AL. Aspirin response: Differences in serum thromboxane B2 levels between clinical studies. Platelets. 2016; 27(3):196-202. PMID: 26270593.
      View in: PubMed
    22. Gremmel T, Frelinger AL, Michelson AD. Soluble CD40 Ligand in Aspirin-Treated Patients Undergoing Cardiac Catheterization. PLoS One. 2015; 10(8):e0134599. PMID: 26237513.
      View in: PubMed
    23. Gerrits AJ, Leven EA, Frelinger AL, Brigstocke SL, Berny-Lang MA, Mitchell WB, Revel-Vilk S, Tamary H, Carmichael SL, Barnard MR, Michelson AD, Bussel JB. Effects of eltrombopag on platelet count and platelet activation in Wiskott-Aldrich syndrome/X-linked thrombocytopenia. Blood. 2015 Sep 10; 126(11):1367-78. PMID: 26224646.
      View in: PubMed
    24. Frelinger AL, Grace RF, Gerrits AJ, Berny-Lang MA, Brown T, Carmichael SL, Neufeld EJ, Michelson AD. Platelet function tests, independent of platelet count, are associated with bleeding severity in ITP. Blood. 2015 Aug 13; 126(7):873-9. PMID: 26138687.
      View in: PubMed
    25. Mumford AD, Frelinger AL, Gachet C, Gresele P, Noris P, Harrison P, Mezzano D. A review of platelet secretion assays for the diagnosis of inherited platelet secretion disorders. Thromb Haemost. 2015 Jul; 114(1):14-25. PMID: 25879272.
      View in: PubMed
    26. Torres AS, Caiafa A, Garner AL, Klopman S, LaPlante N, Morton C, Conway K, Michelson AD, Frelinger AL, Neculaes VB. Platelet activation using electric pulse stimulation: growth factor profile and clinical implications. J Trauma Acute Care Surg. 2014 Sep; 77(3 Suppl 2):S94-S100. PMID: 25159369.
      View in: PubMed
    27. Jakubowski JA, Zhou C, Winters KJ, Lachno DR, Howard J, Payne CD, Mant T, Jurcevic S, Frelinger AL. The effect of prasugrel on ADP-stimulated markers of platelet activation in patients with sickle cell disease. Platelets. 2015; 26(5):474-9. PMID: 25140584.
      View in: PubMed
    28. Hochholzer W, Ruff CT, Mesa RA, Mattimore JF, Cyr JF, Lei L, Frelinger AL, Michelson AD, Berg DD, Angiolillo DJ, O'Donoghue ML, Sabatine MS, Mega JL. Variability of individual platelet reactivity over time in patients treated with clopidogrel: insights from the ELEVATE-TIMI 56 trial. J Am Coll Cardiol. 2014 Jul 29; 64(4):361-8. PMID: 25060370.
      View in: PubMed
    29. Chang H, Yanachkov IB, Dix EJ, Yanachkova M, Li Y, Barnard MR, Wright GE, Michelson AD, Frelinger AL. Antiplatelet activity, P2Y1 and P2Y12 inhibition, and metabolism in plasma of stereoisomers of diadenosine 5',5'?-P¹ ,P4-dithio-P²,P³-chloromethylenetetraphosphate. PLoS One. 2014; 9(4):e94780. PMID: 24722456.
      View in: PubMed
    30. Jakubowski JA, Zhou C, Jurcevic S, Winters KJ, Lachno DR, Frelinger AL, Gupta N, Howard J, Payne CD, Mant TG. A phase 1 study of prasugrel in patients with sickle cell disease: effects on biomarkers of platelet activation and coagulation. Thromb Res. 2014 Feb; 133(2):190-5. PMID: 24368019.
      View in: PubMed
    31. Chang H, Shih LY, Michelson AD, Dunn P, Frelinger AL, Wang PN, Kuo MC, Lin TL, Wu JH, Tang TC. Clinical and laboratory significance of defective P2Y(12) pathway function in patients with myeloproliferative neoplasms: a pilot study. Acta Haematol. 2013; 130(3):181-7. PMID: 23751441.
      View in: PubMed
    32. Jakubowski JA, Zhou C, Small DS, Winters KJ, Lachno DR, Frelinger AL, Howard J, Mant TG, Jurcevic S, Payne CD. A phase 1 study of prasugrel in patients with sickle cell disease: pharmacokinetics and effects on ex vivo platelet reactivity. Br J Clin Pharmacol. 2013 Jun; 75(6):1433-44. PMID: 23171128.
      View in: PubMed
    33. Smith BW, Rozelle SS, Leung A, Ubellacker J, Parks A, Nah SK, French D, Gadue P, Monti S, Chui DH, Steinberg MH, Frelinger AL, Michelson AD, Theberge R, McComb ME, Costello CE, Kotton DN, Mostoslavsky G, Sherr DH, Murphy GJ. The aryl hydrocarbon receptor directs hematopoietic progenitor cell expansion and differentiation. Blood. 2013 Jul 18; 122(3):376-85. PMID: 23723449.
      View in: PubMed
    34. Berny-Lang MA, Jakubowski JA, Sugidachi A, Barnard MR, Michelson AD, Frelinger AL. P2Y12 receptor blockade augments glycoprotein IIb-IIIa antagonist inhibition of platelet activation, aggregation, and procoagulant activity. J Am Heart Assoc. 2013 May 15; 2(3):e000026. PMID: 23676293.
      View in: PubMed
    35. Frelinger AL, Jakubowski JA, Brooks JK, Carmichael SL, Berny-Lang MA, Barnard MR, Heeney MM, Michelson AD. Platelet activation and inhibition in sickle cell disease (pains) study. Platelets. 2014; 25(1):27-35. PMID: 23469943.
      View in: PubMed
    36. Wun T, Soulieres D, Frelinger AL, Krishnamurti L, Novelli EM, Kutlar A, Ataga KI, Knupp CL, McMahon LE, Strouse JJ, Zhou C, Heath LE, Nwachuku CE, Jakubowski JA, Riesmeyer JS, Winters KJ. A double-blind, randomized, multicenter phase 2 study of prasugrel versus placebo in adult patients with sickle cell disease. J Hematol Oncol. 2013 Feb 17; 6:17. PMID: 23414938.
      View in: PubMed
    37. Frelinger AL, Bhatt DL, Lee RD, Mulford DJ, Wu J, Nudurupati S, Nigam A, Lampa M, Brooks JK, Barnard MR, Michelson AD. Clopidogrel pharmacokinetics and pharmacodynamics vary widely despite exclusion or control of polymorphisms (CYP2C19, ABCB1, PON1), noncompliance, diet, smoking, co-medications (including proton pump inhibitors), and pre-existent variability in platelet function. J Am Coll Cardiol. 2013 Feb 26; 61(8):872-9. PMID: 23333143.
      View in: PubMed
    38. Saucedo JF, Angiolillo DJ, DeRaad R, Frelinger AL, Gurbel PA, Costigan TM, Jakubowski JA, Ojeh CK, Duvvuru S, Effron MB. Decrease in high on-treatment platelet reactivity (HPR) prevalence on switching from clopidogrel to prasugrel: insights from the switching anti-platelet (SWAP) study. Thromb Haemost. 2013 Feb; 109(2):347-55. PMID: 23223867.
      View in: PubMed
    39. Frelinger AL, Lee RD, Mulford DJ, Wu J, Nudurupati S, Nigam A, Brooks JK, Bhatt DL, Michelson AD. A randomized, 2-period, crossover design study to assess the effects of dexlansoprazole, lansoprazole, esomeprazole, and omeprazole on the steady-state pharmacokinetics and pharmacodynamics of clopidogrel in healthy volunteers. J Am Coll Cardiol. 2012 Apr 3; 59(14):1304-11. PMID: 22464259.
      View in: PubMed
    40. Psaila B, Bussel JB, Linden MD, Babula B, Li Y, Barnard MR, Tate C, Mathur K, Frelinger AL, Michelson AD. In vivo effects of eltrombopag on platelet function in immune thrombocytopenia: no evidence of platelet activation. Blood. 2012 Apr 26; 119(17):4066-72. PMID: 22294727.
      View in: PubMed
    41. Mega JL, Hochholzer W, Frelinger AL, Kluk MJ, Angiolillo DJ, Kereiakes DJ, Isserman S, Rogers WJ, Ruff CT, Contant C, Pencina MJ, Scirica BM, Longtine JA, Michelson AD, Sabatine MS. Dosing clopidogrel based on CYP2C19 genotype and the effect on platelet reactivity in patients with stable cardiovascular disease. JAMA. 2011 Nov 23; 306(20):2221-8. PMID: 22088980.
      View in: PubMed
    42. Scheer FA, Michelson AD, Frelinger AL, Evoniuk H, Kelly EE, McCarthy M, Doamekpor LA, Barnard MR, Shea SA. The human endogenous circadian system causes greatest platelet activation during the biological morning independent of behaviors. PLoS One. 2011; 6(9):e24549. PMID: 21931750.
      View in: PubMed
    43. Frelinger AL, Michelson AD, Wiviott SD, Trenk D, Neumann FJ, Miller DL, Jakubowski JA, Costigan TM, McCabe CH, Antman EM, Braunwald E. Intrinsic platelet reactivity before P2Y12 blockade contributes to residual platelet reactivity despite high-level P2Y12 blockade by prasugrel or high-dose clopidogrel. Results from PRINCIPLE-TIMI 44. Thromb Haemost. 2011 Aug; 106(2):219-26. PMID: 21713327.
      View in: PubMed
    44. Rahangdale S, Yeh SY, Novack V, Stevenson K, Barnard MR, Furman MI, Frelinger AL, Michelson AD, Malhotra A. The influence of intermittent hypoxemia on platelet activation in obese patients with obstructive sleep apnea. J Clin Sleep Med. 2011 Apr 15; 7(2):172-8. PMID: 21509332.
      View in: PubMed
    45. Angiolillo DJ, Badimon JJ, Saucedo JF, Frelinger AL, Michelson AD, Jakubowski JA, Zhu B, Ojeh CK, Baker BA, Effron MB. A pharmacodynamic comparison of prasugrel vs. high-dose clopidogrel in patients with type 2 diabetes mellitus and coronary artery disease: results of the Optimizing anti-Platelet Therapy In diabetes MellitUS (OPTIMUS)-3 Trial. Eur Heart J. 2011 Apr; 32(7):838-46. PMID: 21252171.
      View in: PubMed
    46. Angiolillo DJ, Saucedo JF, Deraad R, Frelinger AL, Gurbel PA, Costigan TM, Jakubowski JA, Ojeh CK, Effron MB. Increased platelet inhibition after switching from maintenance clopidogrel to prasugrel in patients with acute coronary syndromes: results of the SWAP (SWitching Anti Platelet) study. J Am Coll Cardiol. 2010 Sep 21; 56(13):1017-23. PMID: 20846599.
      View in: PubMed
    47. Frelinger AL, Barnard MR, Fox ML, Michelson AD. The Platelet Activity After Clopidogrel Termination (PACT) study. Circ Cardiovasc Interv. 2010 Oct; 3(5):442-9. PMID: 20736449.
      View in: PubMed
    48. Frelinger AL. Platelet reactivity with prolonged aspirin treatment--steady going at 2 year. Circ J. 2010 Jun; 74(6):1077-8. PMID: 20472961.
      View in: PubMed
    49. Lajer M, Tarnow I, Michelson AD, Jorsal A, Frelinger AL, Parving HH, Rossing P, Tarnow L. Soluble CD40 ligand is elevated in type 1 diabetic nephropathy but not predictive of mortality, cardiovascular events or kidney function. Platelets. 2010; 21(7):525-32. PMID: 20701458.
      View in: PubMed
    50. Frelinger AL, Li Y, Linden MD, Barnard MR, Fox ML, Christie DJ, Furman MI, Michelson AD. Association of cyclooxygenase-1-dependent and -independent platelet function assays with adverse clinical outcomes in aspirin-treated patients presenting for cardiac catheterization. Circulation. 2009 Dec 22; 120(25):2586-96. PMID: 19996015.
      View in: PubMed
    51. Chang H, Yanachkov IB, Michelson AD, Li Y, Barnard MR, Wright GE, Frelinger AL. Agonist and antagonist effects of diadenosine tetraphosphate, a platelet dense granule constituent, on platelet P2Y1, P2Y12 and P2X1 receptors. Thromb Res. 2010 Feb; 125(2):159-65. PMID: 19945153.
      View in: PubMed
    52. Tarnow I, Michelson AD, Barnard MR, Frelinger AL, Aasted B, Jensen BR, Parving HH, Rossing P, Tarnow L. Nephropathy in type 1 diabetes is associated with increased circulating activated platelets and platelet hyperreactivity. Platelets. 2009 Nov; 20(7):513-9. PMID: 19852691.
      View in: PubMed
    53. Michelson AD, Frelinger AL, Braunwald E, Downey WE, Angiolillo DJ, Xenopoulos NP, Jakubowski JA, Li Y, Murphy SA, Qin J, McCabe CH, Antman EM, Wiviott SD. Pharmacodynamic assessment of platelet inhibition by prasugrel vs. clopidogrel in the TRITON-TIMI 38 trial. Eur Heart J. 2009 Jul; 30(14):1753-63. PMID: 19435740.
      View in: PubMed
    54. Tarnow I, Kristensen AT, Krogh AK, Frelinger AL, Barnard MR, Michelson AD. Effects of physiologic agonists on canine whole blood flow cytometry assays of leukocyte-platelet aggregation and platelet activation. Vet Immunol Immunopathol. 2008 Jun 15; 123(3-4):345-52. PMID: 18405981.
      View in: PubMed
    55. Wiviott SD, Trenk D, Frelinger AL, O'Donoghue M, Neumann FJ, Michelson AD, Angiolillo DJ, Hod H, Montalescot G, Miller DL, Jakubowski JA, Cairns R, Murphy SA, McCabe CH, Antman EM, Braunwald E. Prasugrel compared with high loading- and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: the Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation-Thrombolysis in Myocardial Infarction 44 trial. Circulation. 2007 Dec 18; 116(25):2923-32. PMID: 18056526.
      View in: PubMed
    56. Frelinger AL, Jakubowski JA, Li Y, Barnard MR, Fox ML, Linden MD, Sugidachi A, Winters KJ, Furman MI, Michelson AD. The active metabolite of prasugrel inhibits ADP-stimulated thrombo-inflammatory markers of platelet activation: Influence of other blood cells, calcium, and aspirin. Thromb Haemost. 2007 Jul; 98(1):192-200. PMID: 17598013.
      View in: PubMed
    57. Tarnow I, Michelson AD, Frelinger AL, Linden MD, Li Y, Fox ML, Barnard MR, O'Sullivan BP. Cystic fibrosis heterozygotes do not have increased platelet activation. Thromb Res. 2007; 121(2):159-62. PMID: 17532368.
      View in: PubMed
    58. Michelson AD, Frelinger AL, Furman MI. Current options in platelet function testing. Am J Cardiol. 2006 Nov 20; 98(10A):4N-10N. PMID: 17097417.
      View in: PubMed
    59. Frelinger AL, Furman MI, Linden MD, Li Y, Fox ML, Barnard MR, Michelson AD. Residual arachidonic acid-induced platelet activation via an adenosine diphosphate-dependent but cyclooxygenase-1- and cyclooxygenase-2-independent pathway: a 700-patient study of aspirin resistance. Circulation. 2006 Jun 27; 113(25):2888-96. PMID: 16785341.
      View in: PubMed
    60. Frelinger AL, Michelson AD. Clopidogrel linking evaluation of platelet response variability to mechanism of action. J Am Coll Cardiol. 2005 Aug 16; 46(4):646-7. PMID: 16098429.
      View in: PubMed
    61. O'Sullivan BP, Linden MD, Frelinger AL, Barnard MR, Spencer-Manzon M, Morris JE, Salem RO, Laposata M, Michelson AD. Platelet activation in cystic fibrosis. Blood. 2005 Jun 15; 105(12):4635-41. PMID: 15705796.
      View in: PubMed
    62. Linden MD, Frelinger AL, Barnard MR, Przyklenk K, Furman MI, Michelson AD. Application of flow cytometry to platelet disorders. Semin Thromb Hemost. 2004 Oct; 30(5):501-11. PMID: 15497093.
      View in: PubMed
    63. Furman MI, Krueger LA, Linden MD, Barnard MR, Frelinger AL, Michelson AD. Release of soluble CD40L from platelets is regulated by glycoprotein IIb/IIIa and actin polymerization. J Am Coll Cardiol. 2004 Jun 16; 43(12):2319-25. PMID: 15193700.
      View in: PubMed
    64. Frelinger AL, Furman MI, Barnard MR, Krueger LA, Dae MW, Michelson AD. Combined effects of mild hypothermia and glycoprotein IIb/IIIa antagonists on platelet-platelet and leukocyte-platelet aggregation. Am J Cardiol. 2003 Nov 1; 92(9):1099-101. PMID: 14583364.
      View in: PubMed
    65. Marciniak SJ, Mascelli MA, Furman MI, Michelson AD, Jakubowski JA, Jordan RE, Marchese PJ, Frelinger AL. An additional mechanism of action of abciximab: dispersal of newly formed platelet aggregates. Thromb Haemost. 2002 Jun; 87(6):1020-5. PMID: 12083481.
      View in: PubMed
    For assistance with using Profiles, please refer to the online tutorials or contact UMMS Help Desk or call 508-856-8643.
    Frelinger's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts Expand Description
    _
    Co-Authors Expand Description
    _
    Similar People Expand Description
    _
    Same Department Expand Description